ArticleCancers2020
Pharmacokinetic Analysis of Dynamic Contrast-Enhanced Magnetic Resonance Imaging at 7T for Breast Cancer Diagnosis and Characterization.
Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Breast DCE-MRI morphological features and semi-quantitative parameters associated with upgrade to invasive carcinoma in biopsyproven DCIS.Radiology and oncology · 2026Article
- Diagnostic Performance of CT, MRI, and ERUS in Preoperative T- and N-Staging of Colorectal Cancer: A Retrospective Single-Center Analysis.Journal of gastrointestinal cancer · 2026Article
- Non-invasive PD-L1 stratification in non-small cell lung cancer using dynamic contrast-enhanced MRI.European radiology · 2025Article
- Safety Clearance and Artifact Testing of a Nitinol Breast Biopsy Clip in an Ultra-High Resolution (7 Tesla) Magnetic Resonance Imaging Environment.The Indian journal of radiology & imaging · 2025Article
- Validation of Clinical Dynamic Contrast-Enhanced Magnetic Resonance Imaging Perfusion Modeling and Neoadjuvant Chemotherapy Response Prediction in Breast Cancer UsingJCO clinical cancer informatics · 2025Article
- Performance of low- and high-temporal-resolution DCE-MRI texture analysis in distinguishing breast lesions from background enhancement.American journal of translational research · 2025Article
- Differentiation of histological calcification classifications in breast cancer using ultrashort echo time and chemical shift-encoded imaging MRI.Frontiers in oncology · 2024Article
- Predictive Value of Preoperative Dynamic Contrast-Enhanced MRI Imaging Features in Breast Cancer Patients with Postoperative Recurrence Time.Emergency medicine international · 2022Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The purpose of this study was to investigate whether ultra-high-field dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) of the breast at 7T using quantitative pharmacokinetic (PK) analysis can differentiate between benign and malignant breast tumors for improved breast cancer diagnosis and to predict molecular subtypes, histologic grade, and proliferation rate in breast cancer. In this prospective study, 37 patients with 43 lesions suspicious on mammography or ultrasound underwent bilateral DCE-MRI of the breast at 7T. PK parameters (K
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.